Fractyl Health, Inc. (NASDAQ:GUTS) Sees Significant Decrease in Short Interest

Fractyl Health, Inc. (NASDAQ:GUTS) saw a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 2,400,000 shares, a decrease of 12.1% from the January 15th total of 2,730,000 shares. Based on an average daily volume of 355,300 shares, the days-to-cover ratio is presently 6.8 days. Currently, 11.6% of the company’s shares are sold short.

Fractyl Health Stock Down 3.2 %

Fractyl Health stock traded down $0.05 during midday trading on Tuesday, hitting $1.53. 254,139 shares of the company were exchanged, compared to its average volume of 381,747. The company’s fifty day moving average price is $1.89 and its 200-day moving average price is $2.33. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.58 and a quick ratio of 5.57. The company has a market cap of $73.59 million and a PE ratio of -0.13. Fractyl Health has a fifty-two week low of $1.37 and a fifty-two week high of $10.50.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley dropped their price target on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd.

Insiders Place Their Bets

In other Fractyl Health news, CEO Harith Rajagopalan sold 90,972 shares of Fractyl Health stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $1.82, for a total value of $165,569.04. Following the completion of the sale, the chief executive officer now owns 491,329 shares in the company, valued at $894,218.78. The trade was a 15.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jay David Caplan sold 22,346 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $1.81, for a total transaction of $40,446.26. Following the transaction, the insider now directly owns 153,544 shares of the company’s stock, valued at approximately $277,914.64. This represents a 12.70 % decrease in their position. The disclosure for this sale can be found here.

Institutional Trading of Fractyl Health

Several hedge funds have recently made changes to their positions in the stock. Nuveen Asset Management LLC boosted its stake in Fractyl Health by 61.5% during the 4th quarter. Nuveen Asset Management LLC now owns 72,958 shares of the company’s stock valued at $150,000 after purchasing an additional 27,778 shares in the last quarter. Blackstone Inc. purchased a new stake in Fractyl Health in the 4th quarter worth about $212,000. 683 Capital Management LLC boosted its position in Fractyl Health by 4.0% during the 4th quarter. 683 Capital Management LLC now owns 650,000 shares of the company’s stock worth $1,339,000 after acquiring an additional 25,000 shares during the period. Jane Street Group LLC grew its position in Fractyl Health by 125.8% during the fourth quarter. Jane Street Group LLC now owns 22,700 shares of the company’s stock valued at $47,000 after purchasing an additional 12,648 shares in the last quarter. Finally, Silverarc Capital Management LLC increased its stake in shares of Fractyl Health by 6.2% in the fourth quarter. Silverarc Capital Management LLC now owns 176,922 shares of the company’s stock worth $364,000 after acquiring an additional 10,256 shares during the last quarter.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.